On Jun. 26, 2025, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), comprised of leading medical and public health experts who advise the CDC on the safety, effectiveness, and clinical necessity of vaccines, announced the approval of the following vaccines:

• To approve, by a vote of five to two, one dose of clesrovimab, a monoclonal antibody for infants whose mothers are not protected by maternal respiratory syncytial virus (RSV) vaccination. Clesrovimab is one of two RSV monoclonal antibody products available.
• To approve, by a vote of seven to zero, the updated Vaccines for Children Program resolution for prevention of RSV.
• To reaffirm recommendation, by a vote of six to zero, for routine annual influenza vaccination of all persons aged over six months who do not have contraindications.
• To recommend, by a vote of five to one, for children 18 years and younger to receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative.
• To recommend, by a vote of five to one, that pregnant women receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative.
• To recommend, by a vote of five to one, that all adults receive seasonal influenza vaccines only in single-dose formulations that are free of thimerosal as a preservative.

Recommendations made by the ACIP are reviewed by the CDC Director, and if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report.